tm logo
RNAGADE
Live/Pending
THIRD EXTENSION - GRANTED

granted

on 24 Oct 2024

Last Applicant/ Owned by

500 Forge Rd.

Watertown

MA

02472

Serial Number

90545040 filed on 24th Feb 2021

Registration Number

N/A

Correspondent Address

Jonathan M. Gelchinsky

Jonathan M. Gelchinsky Pierce Atwood LLP

Portland, ME 04101

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

RNAGADE

Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardio Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 90545040

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 39957/3542RN

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
24th Oct 2024SOU EXTENSION 3 FILED
24th Oct 2024SOU EXTENSION 3 GRANTED
24th Oct 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24th Oct 2024SOU TEAS EXTENSION RECEIVED
04th Oct 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
04th Oct 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04th Oct 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
04th Oct 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04th Oct 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10th Apr 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED